Chemesis in Colombia: The Place to Be for South American Cannabis, Plus Exclusive CEO Interview


Robin Lefferts

February 28th, 2019

Exclusive, News, Top Story


Cannabis industry research firm Prohibition Partners anticipates the legal cannabis industry in Latin America will reach $12.7 billion in annual sales by 2028. Uruguay led the way in the legalization movement, making recreational cannabis legal in 2013. No other countries have made that step, but several have legalized medical programs in the years since. Still, Colombia is currently the only country whose government is aggressively promoting cannabis exports, making that country the current hot spot for cannabis development.

One company aggressively moving on the opportunity in Colombia is Chemesis International Inc. (CSE: CSI) (OTCQB: CADMF) (FRA: CWAA). Chemesis owns a licensed cultivator there, growing on more than a thousand acres as well as in a 10,000 sqft greenhouse. The company is also building a GMP-certified production lab and extraction facility in Bogota with an eye toward both the Colombian domestic and the international export markets.

Please click here to follow Chemesis’ corporate developments.

Chemesis International CEO Edgar Montero discusses the company’s operations in Colombia and its presence in Puerto Rico, among other things, in Part II of CFN Media’s exclusive interview.

 

Colombia’s Advantages

In early 2018, the Colombian government’s Drug Control Fund authorized the harvest of up to 40.5 tons of medical marijuana for export purposes. The agency estimates that at full capacity, the country could supply about 44% of the world’s current demand for medical marijuana products. The program is just getting off the ground, however, and the country is a long way from reaching that production level.

The combination of a government-directed focus on exports, an ideal growing climate, and very low cost of production makes Colombia a crucial focus for near-term development. The country also boasts a population of about 6 million medical marijuana patients. One interesting aspect of the country’s laws is the general prohibition on the sale of cannabis flower. Companies operating there are necessarily focused on oils and extracted products, areas of the market that offer higher margins and are generally more attractive to consumers anyway.

Please click here to follow Chemesis’ corporate developments.

Chemesis’ Colombian Operations

Chemesis has been working closely with the Colombian government since acquiring subsidiary La Finca Interacviva-Archna Med SAS to expand its existing licensed operations in the country. La Finca is currently licensed to cultivate, produce extracted products, and distribute those products domestically. La Finca is a founding member of Colombia’s Association for the Promotion of Hemp Growing, and has established relationships with over 2,000 farming families throughout the country. It is partnered with Colombia’s largest university for research and development, and is involved in farmer education programs across the country.

La Finca currently offers cannabinoid-based cosmetic products and is expanding its product lines as the company grows. La Finca anticipates achieving export capabilities upon completion of its GMP-certified production facility in Bogota, opening up a much wider market for its derivative product lines.

Looking Ahead

Colombia recently announced a renewed focus on prosecuting the cannabis black market in the country, which has only solidified the country’s legal medical program. That program is just finding its legs, and many companies establishing operations there are kind of building from scratch in a market still in its infancy. By acquiring La Finca, a company that has been operational in Colombia since 2017 and has extensive relationships throughout the country, Chemesis has positioned itself as a strong early mover in what could prove to be an international hub of low cost, high quality, high volume production for the international cannabis market.

Investors may want to keep an eye out for Colombian developments as the company also expands its existing operations in the California and Puerto Rico markets. Chemesis’ focus on cannabis extracts and derived products in key markets looks promising as demand rises across the globe.

Please click here to follow Chemesis’ corporate developments.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Avatar

About Robin Lefferts



Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading